Subscribe

TON - October 2019, Vol 12, No 5

Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Gliomas
Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Gliomas
By Wayne Kuznar
Emerging Therapies
TON - October 2019, Vol 12, No 5
Chicago, IL—High-grade gliomas harboring the histone 3 (H3) K27M mutation are lethal brain tumors associated with a poor prognosis. At the 2019 American Society of Clinical Oncology Annual Meeting, results from a clinical trial showed that treatment with ONC201, a unique, small molecule DRD2 antagonist, resulted in durable tumor regression in adults with recurrent high-grade H3 K27M-mutant gliomas. Read More ›
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
By Phoebe Starr
Geriatric Cancer
TON - October 2019, Vol 12, No 5
Chicago, IL—Reduced-dose chemotherapy is as effective as full-dose chemotherapy in frail elderly patients with advanced gastroesophageal cancer, according to results of the phase 3 GO2 clinical trial presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Lower doses of oxaliplatin plus capecitabine (OCap) led to similar survival but improved quality of life compared with higher doses of that regimen in this patient population. Read More ›
FDA Approves Inrebic for the Treatment of Patients with Myelofibrosis
FDA Updates
TON - October 2019, Vol 12, No 5
On August 16, 2019, the FDA approved fedratinib (Inrebic; Celgene) for the treatment of patients with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–essential thrombocythemia) myelofibrosis. Read More ›
Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities
Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities
By Phoebe Starr
Leukemia
TON - October 2019, Vol 12, No 5
In the phase 3 CLL14 clinical trial, fixed-duration venetoclax plus obinutuzumab was superior to chlor­ambucil plus obinutuzumab as front-line therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities. The fixed-duration regimen significantly improved progression-free survival (PFS), complete response (CR) rate, and minimal residual disease (MRD) negativity versus chlorambucil plus obinutuzumab, and was superior in patients with poor prognostic factors, such as unmutated IGHV and TP53 alterations. Read More ›

Page 2 of 2

  • 1
  • 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.